ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0676

Presentation and Outcomes in Patients with Adrenal Hemorrhage Associated with Antiphospholipid Syndrome: A Cohort Study and Systematic Review of Literature

Jose A Meade-Aguilar1, Gabriel Figueroa Parra1, Jeffrey X. Yang1, Hannah Langenfeld2, Prerna Dogra1, Irina Bancos3, Hassan Murad3, Cynthia Crowson4 and Ali Duarte-Garcia1, 1Mayo Clinic, Rochester, MN, 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, 4Mayo Clinic, Eyota, MN

Meeting: ACR Convergence 2022

Keywords: antiphospholipid syndrome, Cohort Study, Diagnostic criteria, Mortality, prognostic factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Antiphospholipid Syndrome Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: To describe the clinical characteristics, therapies, and outcomes of patients with antiphospholipid syndrome (APS) and adrenal hemorrhage (AH).

Methods: We performed a multicenter retrospective cohort study identifying patients with APS and AH, up to December 12, 2021. We included patients with APS meeting the Sydney criteria and an episode of AH, defined as the presence of imaging consistent with AH or a biopsy revealing hemorrhagic infarction of the adrenal glands.

A Systematic Review of the Literature (SLR) was performed according to the PRISMA guidelines. We did a comprehensive search in multiple databases from their inception to October 20, 2021, in any language. Two reviewers independently screened and reviewed the articles and extracted information. We included case reports/case series reporting cases that met the inclusion criteria used for the cohort. Extracted data included demographics and clinical characteristics at presentation, laboratory data, radiologic findings, therapeutic strategies, and clinical outcomes. Descriptive statistics were used to summarize data. Survival analysis (Kaplan-Meier and Cox models) were used on the cohort only to evaluate factors associated with mortality and radiological remission.

Results: 240 patients were included, 59 (25%) from the cohort and 181 (75%) from the SLR. The mean age was 46.8 (14.96) years, and 44% were female. The median time of APS duration before AH was 3.8 years, and the median follow-up was 10.8 months. History of venous thrombosis was present in 65%, a prior stroke in 12%, and obstetric morbidity in 24%. The most common non-thrombotic APS manifestation was thrombocytopenia (46%), and 21% of the patients had SLE. 80% of the patients had a positive LA, 76% anticardiolipin (aCL) IgG, 46% aCL IgM, 57% anti-β2 glycoprotein-I (β2GPI) IgG, and 36% β2GPI IgM. At presentation, 46% of patients had nausea/vomiting, 80% abdominal pain, and 31% hypotension (Table 1). 83% had a CT scan imaging consistent with acute adrenal hematoma, and 69% of these were bilateral. Adrenal insufficiency was present in 63%, and 47% received hydrocortisone as hormonal substitutive therapy. 58% were receiving anticoagulation before AH and 73% received anticoagulation as treatment. Analysis derived from the cohort showed that radiological remission was documented in 6.6% at 1-year and 41.4% at 5-year follow-ups (Figure 1A). Radiological remission was less likely among those with thrombocytopenia (HR: 0.35) (Figure 2). Death was reported in 27% of patients, with a rate of 1.7% at 1-year and 11.3% at 5-years (Figure 1B). Positive β2GPI IgG and IgM were significantly associated with mortality (HR: 2.66 and 3.32, respectively).

Conclusion: AH is a rare manifestation of APS; the majority of the patients have bilateral adrenal gland involvement. Most patients will develop adrenal insufficiency. Thrombocytopenia is associated with AH and persistent hemorrhage in imaging. Positivity to β2GPI was associated with mortality.

Supporting image 1

Table 1. Clinical manifestations and laboratory data of the cohort and systematic review, at presentation of patients with adrenal hemorrhage and antiphospholipid syndrome.

Supporting image 2

Figure 1. Cumulative incidence of (A) radiological remission and (B) mortality in patients in patients from the cohort with adrenal hemorrhage and antiphospholipid syndrome.

Supporting image 3

Figure 2. Hazard Ratios (95% IC) adjusted for sex and age of variables associated with radiological remission and mortality in patients with incident adrenal hemorrhage and antiphospholipid syndrome.


Disclosures: J. Meade-Aguilar, None; G. Figueroa Parra, None; J. Yang, None; H. Langenfeld, None; P. Dogra, None; I. Bancos, hra pharma, corcept, recordati, spruce, sparrow, lantheus, adrenas; H. Murad, None; C. Crowson, None; A. Duarte-Garcia, None.

To cite this abstract in AMA style:

Meade-Aguilar J, Figueroa Parra G, Yang J, Langenfeld H, Dogra P, Bancos I, Murad H, Crowson C, Duarte-Garcia A. Presentation and Outcomes in Patients with Adrenal Hemorrhage Associated with Antiphospholipid Syndrome: A Cohort Study and Systematic Review of Literature [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/presentation-and-outcomes-in-patients-with-adrenal-hemorrhage-associated-with-antiphospholipid-syndrome-a-cohort-study-and-systematic-review-of-literature/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/presentation-and-outcomes-in-patients-with-adrenal-hemorrhage-associated-with-antiphospholipid-syndrome-a-cohort-study-and-systematic-review-of-literature/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology